On July 10, 2025, the U.S. Senate Appropriations Committee approved a one-year delay in implementing the controversial hemp product ban proposed in the House Appropriations Bill—thanks to an amendment championed by Senator Jeff Merkley (D-OR). Although the approval throws the hemp industry into an abyss of unnecessary uncertainty, this delay offers a critical window to shift the conversation from prohibition to purposeful regulation.
The Harris Hemp Amendment sought to ban all consumable hemp products containing any quantifiable amount of THC, industry experts and advocates—including myself—have warned that such sweeping language would devastate the hemp sector, including non-intoxicating CBD products that contain trace THC due to natural extraction processes.
Senator Merkley acknowledged the need to curb intoxicating lab-made cannabinoids but cautioned against collateral damage to legitimate wellness products. His amendment reflects a growing bipartisan recognition that nuanced, science-based regulation is essential to protect consumers, support farmers, and preserve access to safe, non-intoxicating hemp-derived supplements.
This one-year delay is not a victory lap—it’s a call to action. We must use this time to advocate for a regulatory framework that distinguishes between synthetic intoxicants and naturally occurring cannabinoids, prioritizes product safety, and respects the therapeutic value of hemp.
Let’s work together to ensure that the next iteration of hemp legislation reflects integrity, innovation, and inclusivity—not fear-based policymaking.
